National Infection and Sepsis Audit – Acute NHS settings

The contract for the Infection and Sepsis Audit - Acute care settings (NISA-Acute) will initially be delivered for NHS-funded care in England and Wales for a period of three years, at a maximum total budget of up to £ 1,146,300.00 excl VAT and £1,375,560.00 with VAT.
Bids exceeding these limits will be rejected.
All pricing submissions must be in regard to this 'core' value, and not inclusive of any extension costs or aspirational intent costs, i.e. Please only submit a cost schedule up to the maximum core value of £ 1,146,300.00 excl VAT and £1,375,560.00 with VAT.
The maximum budget ‘core’ value excludes the potential two year extension and aspirational intent as described in section 14.3 of Annex A - Service Specification.
Please note, there is no commitment by the Authority at this stage to include any of the below aspirational intent. Taking this aspirational intent into account, including the possibility that a contract extension may be offered for an additional 24 months, the potential ceiling value is £8,988,606.00 GBP including VAT.
This is a new national clinical audit for severe infection and sepsis in acute NHS hospital settings. The aim is to provide benchmarked infection and sepsis care data to identify variation and drive improvement over time.
Sepsis is life-threatening organ dysfunction caused by a dysregulated host response to infection. While it is an unusual complication of developing an infection, it can be triggered by any infection. When people die from an infection, it is most commonly due to sepsis. Sepsis is complex and hard to diagnose, with no single test and symptoms that overlap with other conditions (NHS England Modern Service Framework, 2026)
Severe infections may lead to the development of sepsis, particularly in at-risk groups, and are one of the most common reasons for emergency admission to hospital.
Both infection and sepsis are major causes of morbidity and mortality in the UK, and costly to the NHS and wider economy:
In 2025...